Founder, CEO & Director Question-and-Answer Session Yes, happy to. So we are going through a transition evolution. Really, it's the product of a vision that I laid out when I moved into this role as CEO in January of 2020. Really focused on 2 key objectives. The first was to expand and diversify our technology, really advance new chemistries for antisense technology to expand into siRNA technology using Ionis know-how, even some gene editing, really genetic medicine. And that wasn't as big a lift as you mig ...